Monday, October 27, 2014
Exciting News for EPP Treatment
Exciting news!!! The EMA has recommended granting a marketing authorization under exceptional circumstances for Scenesse (Afamelanotide) for the treatment of erythropoietic protoporphyria (EPP). Scenesse is the first medicine for patients with this condition. We believe the FDA will approve it soon. Thanks to the Porphyria Research Consortium Experts: Karl Anderson, MD, FACP, Herbert Bonkovsky, MD, Montgomery Bissell, MD, Joseph Bloomer, MD, Robert Desnick, PhD, MD and John Phillips, PhD, and to all the research volunteers. You are all Medical Heroes! Thanks to the APF stuff as well.
Read more from the EMA meeting highlights:http://www.ema.europa.eu/ema/index.jsp?curl=pages%2Fnews_and_events%2Fnews%2F2014%2F10%2Fnews_detail_002191.jsp&mid=WC0b01ac058004d5c1
"Remember....Research is the key to your cure!"
Each form of porphyria results from mutations in one of these genes: ALAD , ALAS2 , CPOX , FECH , HMBS , PPOX , UROD , or UROS . ...
Erythropoietic Protoporphyria What is erythropoietic protoporphyria? The word ‘erythropoietic’ means associated with red blood cells (‘...
#PAW2018 This year, each day we will bring you a member story of each type, a Medical Fact on each type, Medications approved ...
Happy Thanksgiving everyone 2017